MedTech Europe response to the European Commission public consultation on potential countermeasures against US tariffs

Posted on 03.04.2025

Following the United States’ imposition of tariffs of up to 25% on imports of steel, aluminium, and certain products containing steel and aluminium from the European Union (EU) and other trading partners, the EU has announced a step-wise approach to protecting EU interests, including a package of new countermeasures on US exports that has undergone a public stakeholder consultation.

MedTech Europe has responded to this public consultation, highlighting high concerns to see several codes for finished medical devices, along with nearly a hundred codes related to inputs for medical technologies (such as raw materials, spare parts, and components), included in the list of products subject to potential EU countermeasures.

In its response, MedTech Europe also reiterated its call for the European Commission to exempt medical devices and in vitro diagnostic medical devices and their essential inputs from any retaliatory tariffs.

The inclusion of such products would negatively impact the costs, access, and quality of care across Europe as well as the competitiveness and attractiveness of the European medical technology industry. This message was also underlined in MedTech Europe’s recently published press release, accessible here.

For more information, please contact Diana Kanecka, Director International Affairs or Dario Belluomini, Manager International Affairs.